Lumexa Imaging Holdings, Inc. (LMRI)
NASDAQ:LMRI
Want to see LMRI full AI Analyst Report?
LMRI Stock Chart & Stats
$9.66
--
Market closed
$9.66
--
Day’s Range― - ―
52-Week Range$6.45 - $19.45
Previous CloseN/A
VolumeN/A
Average Volume (3M)994.08K
Market Cap
$926.22M
Enterprise Value$1.66B
Total Cash (Recent Filing)$51.23M
Total Debt (Recent Filing)$967.45M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding96,080,734
10 Day Avg. Volume805,352
30 Day Avg. Volume994,080
Financial Highlights & Ratios
PEG Ratio0.82
Price to Book (P/B)2.24
Price to Sales (P/S)1.28
P/FCF Ratio-205.07
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue3.20
Enterprise Value/Gross Profit30.48
Enterprise Value/Ebitda34.23
Forecast
1Y Price Target
$15.75Price Target Upside63.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.74
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
Advanced Modality MomentumSustained growth in high-margin advanced modalities (PET +23.1%, MRI +8.2%) increases average revenue per scan and diversifies services. This mix shift supports structurally higher margins and pricing power versus routine imaging, improving long-term unit economics as adoption scales.
Improving Leverage TrajectoryMaterial deleveraging to roughly 1.6x debt/equity and lower interest expense improves financial flexibility and reduces refinancing risk. With lower cash interest burden, free cash flow can be redeployed into growth or further debt reduction, making the balance sheet more durable.
Disciplined Expansion Via De Novos And JVsA clear growth playbook—de novos, tuck-ins, and JVs—enables scalable, capital-efficient network expansion while capturing referral and payor advantages. Steady center openings plus ramping sites create durable volume growth and operational scale benefits over multiple years.
Bears Say
Persistent Negative Net MarginsDespite revenue scale and periodic positive operating results, consistent negative net margins and negative returns on equity indicate earnings volatility and that non-operating items or financing costs still erode shareholder returns. Profitability must stabilize for sustained value creation.
Weakened Cash GenerationA reversal to negative free cash flow and materially weaker operating cash flow signals earnings-to-cash conversion issues or working-capital drag. Persistent FCF volatility constrains reinvestment, raises refinancing risk, and reduces buffer for growth capex or acquisitions over the medium term.
Elevated G&A And Stock-based CompensationMaterially higher public-company costs and a multi-year elevated stock-compensation profile inflate operating expenses, compressing adjusted margins and free cash flow. Until stock-based pay normalizes, profitability and cash-generation improvements could be delayed despite operational gains.
Lumexa Imaging Holdings, Inc. News
LMRI FAQ
What was Lumexa Imaging Holdings, Inc.’s price range in the past 12 months?
Lumexa Imaging Holdings, Inc. lowest stock price was $6.45 and its highest was $19.45 in the past 12 months.
What is Lumexa Imaging Holdings, Inc.’s market cap?
Lumexa Imaging Holdings, Inc.’s market cap is $926.22M.
When is Lumexa Imaging Holdings, Inc.’s upcoming earnings report date?
Lumexa Imaging Holdings, Inc.’s upcoming earnings report date is Apr 01, 2027 which is in 288 days.
How were Lumexa Imaging Holdings, Inc.’s earnings last quarter?
Lumexa Imaging Holdings, Inc. released its earnings results on May 12, 2026. The company reported $0.187 earnings per share for the quarter, beating the consensus estimate of $0.123 by $0.064.
Is Lumexa Imaging Holdings, Inc. overvalued?
According to Wall Street analysts Lumexa Imaging Holdings, Inc.’s price is currently Undervalued.
Does Lumexa Imaging Holdings, Inc. pay dividends?
Lumexa Imaging Holdings, Inc. does not currently pay dividends.
What is Lumexa Imaging Holdings, Inc.’s EPS estimate?
Lumexa Imaging Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumexa Imaging Holdings, Inc. have?
Lumexa Imaging Holdings, Inc. has 96,080,734 shares outstanding.
What happened to Lumexa Imaging Holdings, Inc.’s price movement after its last earnings report?
Lumexa Imaging Holdings, Inc. reported an EPS of $0.187 in its last earnings report, beating expectations of $0.123. Following the earnings report the stock price went down -23.333%.
Which hedge fund is a major shareholder of Lumexa Imaging Holdings, Inc.?
Currently, no hedge funds are holding shares in LMRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumexa Imaging Holdings, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.75 (63.04% Upside)
$15.75 (63.04% Upside)
Blogger Sentiment
Bullish
LMRI Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 391.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $476.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 24.1%
Last 30 Days ▲ 24.1%
Company Description
Lumexa Imaging Holdings, Inc.
Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans, in addition to standard diagnostic and screening services such as X-rays, ultrasounds, and mammography. The company was founded in 2018 and its primary base of operations is in Raleigh, North Carolina.
LMRI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a constructive growth story: revenue and advanced modality volumes expanded (notably PET +23%), adjusted EBITDA held steady at $51.2 million, profitability returned to positive net income, and management reiterated full-year guidance while outlining disciplined growth via de novos, JVs and technology adoption. Near-term headwinds included a roughly $4 million weather and seasonality EBITDA drag, slower routine scans and mammography, higher public company and stock-based compensation costs, and a Q1 free cash flow shortfall. On balance, the operational momentum in high-margin advanced services, improved cash flow trajectory, successful JV and de novo activity, and affirmed guidance outweigh the transitory and timing-related challenges discussed on the call.View all LMRI earnings summariesLMRI Stock 12 Month Forecast
Average Price Target
$15.75
▲(63.04% Upside)
Ownership Overview
0.64% Insiders
12.12% Mutual Funds
10.21% Other Institutional Investors
74.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---